AgomAb Therapeutics NV (AGMB)
NASDAQ
$10.51−$0.0700 (−0.66%) on the dayAs of the close; data may be delayed.
AGMB price, last 12 months
Key stats
- Previous close
- $10.58
- Open
- $10.65
- Day range
- $10.41 – $11.23
- 52-week range
- $8.75 – $17.82
- Volume
- 164K
- Avg volume (20 days)
- 172.7K
- Market cap
- $517.6M
Performance
1W−13.6%
1M−26.4%
3M−23.9%
6M−11.5%
YTD—
1Y—
Technicals and fundamentals
About AgomAb Therapeutics NV
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
- Listed on
- NASDAQ
- Market cap
- $517.6M